Abstract
Resistance of cancer cells to chemotherapy and/or radiotherapy is a major challenge to current anticancer treatment. The NF-κB signaling pathway plays an important role in tumor development and progression, and results in unsatisfactory treatment outcome. Inhibition of the NF-κB signaling cascade may sensitize the resistant cancer cells to chemotherapy and/or radiotherapy. Here, the correlation of NF-κB molecules with carcinogenesis and tumor progression, along with its significance in clinical practice, is reviewed. The potential clinical application of NF-κB and its associated molecules as diagnostic and therapeutic targets is also discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Benzenesulfonates / pharmacology
-
Benzenesulfonates / therapeutic use
-
Combined Modality Therapy
-
Drug Resistance, Neoplasm
-
Humans
-
Molecular Targeted Therapy
-
NF-kappa B / antagonists & inhibitors
-
NF-kappa B / genetics
-
NF-kappa B / metabolism*
-
Neoplasms / diagnosis
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Neoplasms / radiotherapy
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Prognosis
-
Pyridines / pharmacology
-
Pyridines / therapeutic use
-
Radiation Oncology
-
Radiation Tolerance / drug effects
-
Signal Transduction
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
NF-kappa B
-
Phenylurea Compounds
-
Pyridines
-
Niacinamide
-
Sorafenib